Dimethyl fumarate (Skilarence®) was newly registered in 2017 for the treatment of psoriasis. This is not a new drug, as it has been available as an unlicensed product for decades. After the registration, the drug was made more expensive. Its short-term effectiveness for the treatment of psoriasis has now been proven in randomised research. There have been no studies of its effectiveness in the longer term. Its frequent gastrointestinal adverse effects limit the suitability of dimethyl fumarate.

**Ge-Bu Indication**

**Literature references**

**Authors**

- Leo M.L. Stolk